Context:

After tumor removal in recurrent glioblastoma, a collagen tile embedded with radioactive seeds delivers targeted, short-range radiation within about 8 millimeters for roughly one month, enabling immediate post-surgery treatment without delaying wound healing. In 22 patients, the approach showed a favorable safety profile with no post-procedural wound infections or radiation-related toxicity and allowed the tumor area to be treated while the brain heals. Local control remained high, at 86% at 6 months and 81% at 12 months, with median progression-free survival around 8 months and median overall survival extending to about 20 months for unmethylated MGMT and 37 months for methylated MGMT. The therapy is described as a one-and-done option that avoids weeks of external radiation, potentially redefining care for recurrent GBM if larger trials replicate results. While quality-of-life data were not collected, clinicians note patients value not needing repeated hospital visits for radiation.

Dive Deeper:

• GT, or GammaTile therapy, uses radioactive seeds embedded in a collagen tile placed immediately after tumor resection to cover the entire resection cavity and maintain cavity architecture to prevent radiation ‘hot spots’.

• The approach is a brachytherapy variant designed to deliver radiation locally with a short range, minimizing exposure to healthy tissue while the surgical site heals.

• In the study, 22 adults with wild-type IDH glioblastoma undergoing surgery for recurrent tumors were treated, with a mean age of 57.7 years and a mix of MGMT methylated and unmethylated cases.

• Safety outcomes showed no wound infections across subsequent resections and no adverse radiation effects requiring medical or surgical intervention; one hydrocephalus readmission occurred but not attributed to GT radiation.

• Efficacy metrics included 86% local control at 6 months and 81% at 12 months, with a median progression-free survival of about 8 months and overall survival differences tied to MGMT methylation status (≈20 months unmethylated vs ≈37 months methylated).

• The authors highlighted that GT avoids delaying radiation therapy, eliminating a potential window for tumor regrowth and reducing patient burden by eliminating the need for multiple post-surgical visits for external beam radiation.

• Limitations acknowledged include the lack of quality-of-life data, though clinical impressions suggest improved convenience and reduced treatment-related disruptions for patients.